long-acting sequence-modified recombinant factor VIIa (BAY 866150) - Bayer
Deutsche Bank Healthcare Conference (Bayer) - May 7, 2012 - Anticipated initiation of combined P2/3 trial for hemophilia in 2012 
Anticipated trial initiation date • Hemophilia
http://www.larvolonline.com/tlg/ccdb/BayerDeutscheBankHealthcareConferenceMay07'12.pdf
 
May 7, 2012
 
BAY 866150 --- Anticipated initiation of combined P2/3 trial for hemophilia in 2012 ---